Why the study?
What are the survival and weaning outcomes of ventricular assist devices and percutaneous cardiopulmonary support in patients with postoperative cardiogenic shock?
What are the survival and weaning outcomes of ventricular assist devices and percutaneous cardiopulmonary support in patients with postoperative cardiogenic shock?
Ventricular assist devices and percutaneous cardiopulmonary support can successfully salvage a proportion of patients with postoperative cardiogenic shock, with survivors demonstrating good long-term functional recovery.
Answers are grounded in this paper and cite their sources.
Small case series outcomes should not change practice; leaves open need for controlled trials on device selection in postoperative shock.
Over the last 5 years, 15 patients received ventricular assist devices (VADs) (Group 1) and 5 received percutaneous cardiopulmonary support (CPS) (Group 2) while in postoperative cardiogenic shock. Group 1 consisted of 8 men and 7 women ranging in age from 22 to 73 years (average age, 55 years). Nine of these patients underwent surgery for valve replacement, 5 for coronary artery bypass grafting, and 1 for closure of a ventricular septal rupture. The duration of VAD support ranged from 6 h to 9 days (mean, 3.9 days). Group 2 consisted of 4 men and 1 woman ranging in age from 49 to 68 years (average age, 57 years). One of these patients underwent surgery for valve replacement, 1 for coronary artery bypass grafting, 2 for replacement of a thoracic aneurysm, and 1 for left ventricular aneurysmectomy. The duration of CPS ranged from 4 h to 8 days (mean, 2.8 days). In Group 1, 13 patients were weaned from the VADs and 8 survived. Bleeding occurred in 5 patients, renal failure in 4, infection in 3, cardiac failure in 4, cerebral infarction in 1, perioperative myocardial infarction in 1, arrhythmia in 1, and ileus in 1. In Group 2, 4 patients were weaned from the CPS and 3 survived. Bleeding occurred in 3 patients, renal failure in 2, CNS injury in 2, and cardiopulmonary failure in 1. The 8 survivors in Group 1 have been followed for 2 to 56 months (mean, 28.7 months). Five patients were in NYHA class I, 2 were in class II and 1 was in class III.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Murakami et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: